? ? ? 西安慧康企業運營管理集團有限公司(簡稱:慧康集團)成立于2012年?;劭导瘓F以生物科技、美容連鎖為核心業務集群,構建全產業鏈式的國際化企業運營體系,塑造生物科技應用于社會生活的核心價值。
? ? ? ?慧康集團將商業實踐與社會價值相融合,追求新產業時代下的可持續發展,斥資5億元建設的生物科技產業園區,占地40畝,總建筑面積6.5萬平方米,將科研、管理、培訓、生產集于一體。截至2023年2月,慧康集團旗下子公司共有145項專利,包括國家發明專利70項、外觀專利18項、實用新型專利27項,中國香港專利13項、國際專利17項;現有國家I類新藥1項,醫療器械2項,西安市博士后創新基地項目3項,重點科研項目13項。
? ? ? ?陜西慧康生物科技有限責任公司發起的“慧康?中國肽庫”項目(簡稱“中國肽庫”),將建立蛋白與多肽原料研發與供應基地,搶占“藍海戰略”引領下的價值創新高地。
HuiKang Culture
生物科技進化人類生活。
共創、共贏、共享。
為員工謀福利,為企業創價值,為社會做貢獻。
知行合一,敬天愛人。
以人為本、以德為先、機會均等、任賢使能。
董事長 Chairman of the Board
中國資深媒體人,先后擔任《重慶時報》《文化報》《華商報》等多家傳媒高管及負責人,在任陜西華商報社黨委書記、執行社長期間,通過創新產業運營模式,推進多元化經營與全媒體融合,率領華商報業創下歷史最好業績。
資本運營策略師,曾兼任多家上市公司戰略決策顧問,首創“相氏系統管理環”公司戰略與風險管理系統,長期致力于生物科技時代下新經濟法則研究,人類進入生物文明時代倡言者。
Senior media editor in China. He has successively served as the senior executive and principal of many media companies, such as Chongqing Times, Cultural Daily and Huashang Daily. During his tenure as Party Secretary and executive president of Shaanxi Huashang Daily, he led Huashang Newspaper to achieve the best performance in history by innovating the industrial operation mode and promoting the integration of diversified operation & omnimedia convergence.
Capital Operations strategist. He doubled in many listed companies as a strategic counselor, initiated Corporate Strategy and Risk Management System, named "Xiang's System Management Loop", constantly strived to study the new economic laws in the era of biotechnology. He is an advocate of mankind entering the age of biological civilization.
董事 Board Member
發展生物科技,為社會做貢獻,是孫劍先生信奉的宗旨。
近20年的經營中,他對大健康產業、生物科技具有非常執著的信念、前瞻的戰略眼光、卓越的運營能力,以及豐富的管理經驗。
2010年,他基于蛋白與多肽的應用研究,投資發展生物科技大健康業務。目前,已建設并投入使用65000平米慧康生物產業園,配備國際先進的科研以及生產設備、經營范圍涵蓋新藥、基因治療、醫療器械以及化妝品的研發、生產與銷售。
Developing biotechnology and making contributions to society are Mr. Sun’s beliefs.
From nearly 20 years of operation, he got a firm conviction in the massive health industry and biotechnology, along with forward-looking strategic vision, excellent operational capabilities and rich management experience.
In 2010, he invested in the massive health industry based on applied research in proteins and peptides. At present, a 65,000 m2 HuiKang Biological Industrial Park has been built and put into operation with international advanced scientific research and production equipment. The business scope covers the R&D of new drugs, gene therapy, medical devices and the R&D, manufacture and sales of cosmetics.
2021?
Huikang Bio-Tech was the only Chinese enterprise in the new material group of the Global Top 100 Innovative list.
2021?
Huikang Bio-Tech was subsidize by the State Key Laboratory of Mechanical Behavior of Materials, Ministry of Education.
2021?
HuiKang Novel Coronavirus blocking peptide project obtained class I fund of Postdoctoral Innovation Base.
2020?
Argireline Serum received the honor of Shaanxi Key New Products.
2020?
The scientific achievements of collagen have been published in famous academic journal International Journal of Biological Macromolecules.
2020?
The brand ACTII was born.
2019?
HuiKang Biotechnology Industrial Park officially put into operation.
2018?
Successfully hosted the International Protein and Peptides Conference, a sub forum of the 2018 Global Hard and Core Conference and the Belt and Road Innovation conference.
2018?
Introduction article of HuiKang ? China Peptide Bank published in the sub Journal of Nature.
?2017
Launched the Phase I Construction Plan of HuiKang? China Peptide Bank.
?2017
Started Bio-tech cosmetics business.
?2017
The bio-tech cosmetics brand Ye New Skin was debuted.
?2016
Initiate the R&D of two national class I new drugs.
?2012
Xi 'an HuiKang Enterprise Operation Management Group Co., LTD was founded.
?2012
Obtained the first national invention patent.
?2011
HuiKang Biotechnology Industrial Park broke groud and started building.
?2011
A series of skin care products with protein and peptides as the core ingredients have came out after one and another..
?2011
Recombinant human collagen was successfully developed..
?2010
HuiKang R&D Center was set up.
?2001
Shaanxi Dongda Biochemical Technology Co., LTD. (the predecessor of HuiKang Bio-Tech) was established.
截至2022年10月底,慧康集團旗下子公司共有134項專利,包括國家發明專利65項、外觀專利17項、實用新型專利25項,中國香港專利12項、 國際專利15項。
投資5.2億元,占地42畝,建筑面積6.5萬平方米。
合成多肽中試放大系統
蛋白多肽制劑中試放大生產系統
重組蛋白中試放大生產系統
“中國肽庫”項目計劃構建一個序列精準的商業肽庫,或稱平行肽庫,共計超過175000條肽,未來將成為人類共享的寶庫。
?
?
?
Copyright ? 2017 慧康集團保留所有權利/
陜ICP備17008662號-1友情鏈接:
慧康生物研發中心